Recent Updates
Recently added Catalysts
AKBA Positive Sentiment

Akebia Therapeutics to Present at the Jefferies London Healthcare Conference Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease,...

Tuesday, November 12, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Akebia Therapeutics, Inc. will present at the Jefferies London Healthcare Conference on November 21, 2024. CEO John Butler is scheduled to speak at 1:00 PM GMT. The conference runs from November 19-21, 2024, in London, and a webcast of the presentation will be available for 30 days on Akebia's website.
Price reaction · baseline $1.99 (2024-11-11 close) · hit after-hours · 1 other AKBA headline(s) in the window, move may be shared
day 0 close · peak
-2%

Market Sentiment Analysis

POSITIVE FACTORS

  • Akebia Therapeutics is actively engaging with the healthcare community.
  • The presentation at the Jefferies London Healthcare Conference highlights company initiatives.
  • The company aims to improve the lives of those affected by kidney disease.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+1%
120-day peak, hindsight
Typical move
8%
average across 4 past catalysts
Lead asset
ferric
Phase 3 · Anemia of Chronic Kidney Disease

Full Press Release Details

CAMBRIDGE, Mass. , Nov. 12, 2024 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA ), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John Butler , Chief Executive Officer, will present at the Jefferies London Healthcare Conference on Thursday, November 21 at 1:00 PM GMT .
A webcast of the presentation can be accessed through the "Investors" section of Akebia's website at https://ir.akebia.com for 30 days following the conference.
The Jefferies London Healthcare Conference will take place November 19-21, 2024 in London .
About Akebia Therapeutics Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts . For more information, please visit our website at www.akebia.com , which does not form a part of this release.
Akebia Therapeutics Contact Mercedes Carrasco [email protected]

Frequently Asked Questions

When will Akebia present at the Jefferies Conference?

Akebia will present on November 21, 2024, at 1:00 PM GMT.

Who is presenting for Akebia at the conference?

John Butler, the CEO of Akebia Therapeutics, will present.

Where is the Jefferies London Healthcare Conference held?

The conference will take place in London from November 19-21, 2024.

How can I access the presentation?

The presentation will be available via webcast on Akebia's website for 30 days.

ShareAdd on Google
Tags: AKBA Viatris Investor Conferences Healthcare Akebia Therapeutics Jefferies Conference kidney disease John Butler biopharmaceutical
Last updated: Nov 12, 2024

Biotech snapshot

Cash runway
$156M liquidity · $0M/mo burn
Low dilution risk
Lead asset
ferricPhase 3
Anemia of Chronic Kidney Disease →

Catalyst track record

+1%
best trade around AKBA's most recent catalyst

Peak hindsight return over a 120-day window, across 4 tracked FDA/PDUFA catalysts for AKBA.

See every catalyst's timing & PoA →